GuangzhoImageTechnoloo.Ltdasjointly foundedbyAlexperts romSingapore andChina, alongwithaproduct andbusinesteam.ThecmpanyoerstheAl-basedmedicalmag-ing processing and collaboration platform IMage3D 2.0, as wellas intelligent surgical robots, to address various perioperative clinical needs.These needs include preoperative planning,intraoperative navigation, postoperative assessment, surgical plan discussionand sharing, and precise surgical execution.The platform has obtained Singapore HSA certification and serves clinical departments such as neurosurgery, cardiothoracic surgery,hepatobiliary and pancreaticsurgery, gastrointestinal surgery, and orthopedics.It has been implemented in over 20re-nowned hospitals in Singapore and China and has received high praise from users.
Dr. Jia Yin Zhou conducted research at the National University of Singapore and the Agency for Science, Technology and Research in Singapore in 2005. Later, he served as the Chief Scientist at Philips Research East Asia in Shanghai and as the Managing Director of the Singapore Research Center for China's leading surgical robotics company. He has published 51 SCl/El papers,filed and obtainedover 30Chinese andU.S.patents, and led or participated in more than 20 research projects.Dr.Zhou has received five international awards, including first place in the CTLiver Tumor Segmentation Challenge at the Medical Image Computing and Computer-Assisted Intervention (MicAl) conference. She possesses extensive academic and industry experience.
The IMage3D 2.0 medical imaging processing and collaboration platform boasts a response time that isover50%faster than similar products on the market. Over the next year, we aim to reduce the response time from the current 60 minutes to 5-10 minutes, thus winning market competition with accurate results and quick delivery.IMage3D 2.0 is widely used in preopera-tive planning, intraoperative navigation, and surgical plan discussions across various departments. In the future, in conjunc-tion with intelligent surgical robots,it will enable fully automated surgical robots to independently complete surgical plan-ning and execution. The founding team members all come from top-tier research institutions and the industry. They have collectively invested over 200 million yuan in research and development, published more than 200 papers, secured nearly 100 patents in China and the United States, and received over 10 international awards.